OmniComm Infographic eSource Easier Than You Think

CSL partners with Alentis Therapeutics to co-develop lixudebart, while Jiangsu Nhwa licenses a clinical-stage sleep disorder candidate to Somnivera.

How earlier signals of misconnection may help pharma identify trust breakdowns before they show up as lagging measures in adherence, initiation, engagement, and outcomes.

Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.

Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.

Foghorn Therapeutics and Eli Lilly are discontinuing their SMARCA2 degrader Fhd-909 after Phase I data fell short on efficacy.

Novartis licenses Abogen's mRNA-encoded CD19xCD3 T-cell engager, while AstraZeneca and Daiichi Sankyo partner with Summit Therapeutics.

CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference.

Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.